Company
Headquarters: Wuhan, China
Employees: 3,091
CN¥10.79 Billion
CNY as of Jan. 1, 2025
US$1.48 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Mayinglong Pharmaceutical Group Co., LTD. engages in the manufacture, wholesale, and retail of pharmaceutical products primarily in China. It offers hemorrhoid, gynecological, cough, skin, functional food, and Chinese medicine drink tablet products, as well as medical devices. The company also sells its products online. It also operates hospitals. Mayinglong Pharmaceutical Group Co., LTD. was founded in 1582 and is based in Wuhan, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥3.48 B |
| EBITDA | CN¥625.0 M |
| Gross Profit TTM | CN¥1.58 B |
| Profit Margin | 13.85% |
| Operating Margin | 19.44% |
| Quarterly Revenue Growth | 7.20% |
Mayinglong Pharmaceutical Group Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600993 wb_incandescent